AFMD News and Press, Affimed N.V. From 06/08/24

2024-06-08 03:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-07 15:00:58 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Citi – ...

MANNHEIM, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2024 results and corporate update on Wednesday, Jun...

MJ Holdings Inc (MJNE) is expected to report for Q1 2024 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.17 for Q1 2024 Fresnillo Plc (FNLPF) is expected to report for Q1 2024 Luna Innovations Incorporated (LUNA) is expected to report $-0.01 for Q1 2024 Cano Health...

A look at the top 10 most actives in the United States Crown Electrokinetics Corp. (CRKN) rose 17.9% to $0.1179 on volume of 290,472,504 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 7.1% to $0.6248 on volume of 223,394,331 shares GameStop Corporation (GME) rose 21.0% to $28...

Affimed N.V. (NASDAQ: AFMD) is one of today's top gainers. The company's shares have moved 74.94% on the day to $7.58. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its l...

In 17 EGFR wild-type ( EGFR wt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months Objective r...

2024-05-29 10:25:06 ET More on Affimed Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript Affimed falls on 1-for-10 reverse stock split Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Aff...

Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the ongoing AFM24-102 phase 1/2a study The FDA’s Fast Track design...

Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...